New discovery paves way for pancreatic cancer treatment

November 11, 2016 by Jessica Sieff
Patients suffering from pancreatic cancer may soon face better treatment options due to the latest discovery by Dr. Reginald Hill, who's research focuses on drugs that are already approved by the FDA to find out why those drugs are not working. Credit: University of Notre Dame/Matt Cashore

Pancreatic cancer, the third leading cause of cancer-related deaths, is projected to be the second by the year 2030, according to a study in the journal of Cancer Research. The five-year survival rate is only 8 percent, making it the only major cancer with a survival rate in the single digits. Despite rising mortality rates, pancreatic cancer is under-researched and underfunded, and there are few Food and Drug Administration-approved treatments to combat the disease.

With the current pipeline for drug discovery taking 10 to 15 years from the laboratory to use, and an estimated 41,780 who will die from the disease this year alone, time is of the essence.

Now, patients suffering from pancreatic cancer may soon face better treatment options due to the latest discovery by Dr. Reginald Hill, Archibald Assistant Professor of Cancer Biology at the University of Notre Dame and researcher at the Harper Cancer Research Institute. Hill's research focuses on drugs that are already approved by the FDA to find out why those drugs are not working in patients with pancreatic cancer.

"The bulk of a pancreatic cancer tumor is made of approximately 10 percent cancer cells and 90 percent . Somehow, the supporting cells have figured out how to survive the chemotherapy," Hill said. "Microscopic vesicles called exosomes, bubbles with genetic material released by cells during chemotherapy exposure, are released from supporting cells, educating the cancer cells on how to survive, resulting in a tumor becoming chemoresistant."

Research in the New England Journal of Medicine has revealed a majority of pancreatic cancer cases have proven to be resistant to chemotherapy and unresponsive to drug treatments found to be effective in other types of cancer.

Most new research has focused on destroying supportive cells. However, those studies concluded that when the supportive cells were attacked, patients actually developed more advanced cancer. "It was like poking holes into the area around the cancer cells and allowing it to spread," he said.

Hill focused on blocking the release of exosomes, preventing the relay of information from supporting cells to —which increased the efficacy of chemotherapy. This recently published study suggests that using an exosome blocker, which is nontoxic, in combination with standard-of-care chemotherapy will those with pancreatic and many other cancers as well.

The lack of effective treatments available to help thousands of those with is what drew Hill to his research. This latest discovery paves the way for those patients to have greater hope.

Explore further: Starving pancreatic cancer cells: Scientists identify potential pancreatic cancer target

More information: K E Richards et al, Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells, Oncogene (2016). DOI: 10.1038/onc.2016.353

Related Stories

Starving pancreatic cancer cells: Scientists identify potential pancreatic cancer target

October 17, 2016
Researchers have found that a protein called SLC6A14 is overexpressed by several fold in pancreatic tumors taken from patients and in cancerous pancreatic cells lines compared with normal pancreatic tissue or normal pancreatic ...

Team discovers potential drug targets to reduce pain in pancreatic cancer patients

November 7, 2016
The Translational Genomics Research Institute (TGen) has discovered potential drug targets to reduce pain in pancreatic cancer patients.

Pancreatic cancer set to become third biggest cancer killer in EU next year

November 7, 2016
The number of deaths from pancreatic cancer will overtake breast cancer mortality rates in the EU in 2017, a study has found.

Pancreatic cancer trial to make tumours more sensitive to treatment

August 30, 2016
Cancer Research UK (CRUK) launches a first-of-its-kind pancreatic cancer clinical trial to make cancer cells more responsive to chemotherapy and radiotherapy, with University of Glasgow researcher Professor Jeff Evans as ...

Immune-based therapy in mice shows promise against pancreatic cancer

July 4, 2016
While immune therapy has proven effective in treating certain types of cancer, especially lung cancer and melanoma, tumors of the pancreas remain among the most difficult to treat and, so far, are impervious to immune-based ...

Targeting pancreatic cancer through signalling

June 14, 2016
Researchers have identified a new way to tailor treatments for patients with pancreatic cancer, one of the most deadly forms of cancer. Currently only five per cent of people with pancreatic cancer survive longer than five ...

Recommended for you

Targeted antibiotic use may help cure chronic myeloid leukaemia

September 19, 2017
The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research.

Brain powered: Increased physical activity among breast cancer survivors boosts cognition

September 19, 2017
It is estimated that up to 75 percent of breast cancer survivors experience problems with cognitive difficulties following treatments, perhaps lasting years. Currently, few science-based options are available to help. In ...

Bone marrow protein a 'magnet' for passing prostate cancer cells

September 19, 2017
Scientists at the University of York have shown that a protein in the bone marrow acts like a 'magnetic docking station' for prostate cancer cells, helping them grow and spread outside of the prostate.

Brain cancer breakthrough could provide better treatment

September 19, 2017
A new discovery about the most common type of childhood brain cancer could transform treatment for young patients by enabling doctors to give the most effective therapies.

Researchers compose guidelines for handling CAR T cell side effects

September 19, 2017
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University ...

A new paradigm for treating transcription factor-driven cancers

September 18, 2017
In the current issue of Proceedings of the National Academy of Sciences, researchers from Nationwide Children's Hospital describe a new paradigm for treating transcription factor-driven cancers. The study focuses on Ewing ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.